What do systematic reviews say?

Clonazepam vs ethosuximide

The review found no eligible studies for this question.

• Clonazepam monotherapy for treating people with newly diagnosed epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Clonazepam vs ethosuximide

The review found no eligible studies for this question.

• Clonazepam monotherapy for treating people with newly diagnosed epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people achieving 50% or greater reduction in monthly… compared with risperidone and previous ASM only (low certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.79 [0.84, 9.24]
  1 study · 56 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.4 [0.44, 4.42]
  1 study · 56 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.8 [1.14, 6.89]
  1 study · 33 participants
  Moderate

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Moderate

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.12, 3.59]
  1 study · 61 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any dose of lacosamide vs placebo

Any dose of lacosamide leads to higher 50% or greater reduction in seizure frequency compared with placebo (high certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.79 [1.55, 2.08]
  5 studies · 2199 participants
  High

Any dose of lacosamide vs placebo

Any dose of lacosamide may leads to higher seizure freedom compared with placebo (low certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 2.27 [1.35, 3.83]
  5 studies · 2199 participants
  Low

Any dose of lacosamide vs placebo

Any dose of lacosamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.57 [1.24, 1.98]
  5 studies · 2199 participants
  Moderate

Any dose of lacosamide vs placebo

Any dose of lacosamide leads to higher dizziness compared with placebo (high certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 2.96
  5 studies · 2199 participants
  High

Any dose of lacosamide vs placebo

Any dose of lacosamide probably leads to higher headache compared with placebo (moderate certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.34
  5 studies · 2199 participants
  Moderate

Any dose of lacosamide vs placebo

Any dose of lacosamide probably leads to higher vomiting compared with placebo (moderate certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 2.94
  5 studies · 2199 participants
  Moderate